Hepatitis B Vaccine Articles

Medeva Beats Expectations At Half Year

12 September 1994

Medeva Losses Out To Biogen On Hep B Patent

8 August 1994

Medeva And Biogen Await Patent Ruling

1 August 1994

European Commission CPMP July Meeting

25 July 1994

SB Sets US Price For Famvir At Same Level As Zovirax

18 July 1994

JAPANESE DRUG APPROVALS

21 March 1994

SMITHKLINE BEECHAM PLEASED WITH RESULTS

28 February 1994

CUBA VACCINE SALES

21 February 1994

INNOGENETICS IMPROVES TNF FOR CANCER THERAPY

21 February 1994

EUROPEAN STOCK COMMENT

24 January 1994

MEDEVA IN DEAL WITH PROTEUS

17 January 1994

EURO CPMP DECISIONS AT DECEMBER MEETING

10 January 1994

EUROPE STOCK COMMENT

15 November 1993

SMITHKLINE BEECHAM ADVANCES IN 3rd QTR

25 October 1993

THERAPEUTIC HELP FOR HEP B SUFFERERS

25 October 1993

PROSPECTS FOR A CANCER VACCINE: MUCIN EPITOPES

11 October 1993

MEDEVA/BIOGEN PATENT CASE STARTS

11 October 1993

BIOGEN IN HEP B VACCINE DISPUTE

11 October 1993

MEDEVA FACES UP TO "GROWING PAINS"

6 September 1993

US NIH INABILITY TO ENFORCE FAIR PRICING

3 May 1993

SMITHKLINE BEECHAM "EXCELLENT PROGRESS"

26 April 1993

PRICE FLEXIBILITY AND THE DRUG INDUSTRY

12 April 1993

PRETAX PROFIT LEAPS AT MEDEVA115%AT MEDEVA IN 1992

15 March 1993

SB BEECHAM RESULTS; EXPLOITS STRENGTHS

1 March 1993

MERCK CANADA MOVES TO WARD OFF COMPETITION

1 March 1993

TANABE LAUNCHES VACCINE

8 February 1993

SIDE EFFECT WITH ENGERIX B VACCINE

1 February 1993

BIOGEN'S EUROPEAN HEP B PATENT

25 January 1993

CYTEL STARTS TRIALS OF ANTIBODY PRODUCT

4 January 1993

MERCK & CO EARNINGS ESTIMATES LOWERED

14 December 1992

HEPATITIS B VACCINE

13 April 1992

MEDEVA ACQUIRES HEP-B PRODUCTS

23 March 1992

UK DRUG STOCKS BULL RUN OVER?

10 February 1992

A REAL NEED FOR SB'S HAVRIX, MEETING HEARS

3 February 1992

ISRAELI HEPATITIS VACCINATION PLAN

27 January 1992

SB HEP A VACCINE APPROVAL

20 January 1992

Showing 101-136 of 136 articles

Go to beginningPreviousNextGo to end